Lifeforce Capital

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines specifically for transplanted livers and the treatment of fatty liver conditions. Founded in 2019 and based in Headington, United Kingdom, the company employs advanced genomic techniques to identify and inhibit overactive genes associated with liver diseases. This approach includes testing therapies in discarded donor livers that are maintained outside the body, ensuring that potential treatments can be evaluated in a relevant biological context. With over 15 years of expertise in liver genomics research, Ochre Bio aims to create a pipeline of innovative medicines that address liver and liver-mediated conditions, ultimately enhancing the availability of healthy livers for transplantation and reducing complications associated with cirrhosis. The company operates within Oxford's biotechnology innovation hub, leveraging its scientific foundation to advance therapeutic solutions in the field of liver health.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

MindRight Health, Inc. is a Newark, New Jersey-based company founded in 2019 that offers mental health coaching via text messaging. Its mission is to promote health equity by providing accessible and inclusive mental health care, particularly for communities of color and low-income families. MindRight partners with healthcare payers and providers to deliver culturally responsive coaching, assigning users to personal coaches who offer support year-round. This approach aims to create a continuum of care that addresses the unique needs of youth and communities that often avoid traditional clinical services due to stigma and limited access. Additionally, MindRight provides its partners with real-time data on community mental health needs, which helps in predicting and preventing mental health crises.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Vivante Health, Inc. is a digital health company focused on addressing digestive health and chronic conditions. Founded in 2016, it has developed GIThrive, a technology platform designed to provide actionable insights for managing digestive issues. GIThrive offers a comprehensive digital gut health program that includes expert guidance, 24/7 support, and personalized care plans. The company also provides GIMate, an innovative portable breathalyzer that identifies trigger foods, and GutCheck, which analyzes gut bacteria to recommend tailored diets. Vivante Health emphasizes individualized care, utilizing a scalable platform that integrates real-time data from biometric devices and partners. This approach not only aims to reduce healthcare costs and improve employee health for large employers and health plans but also enhances user empowerment through advanced science and technology. Headquartered in Houston, Texas, with an additional office in Athens, Greece, Vivante Health continues to prioritize innovative solutions in the realm of digestive health.

Synapticure is a virtual clinical care platform dedicated to supporting patients with neurodegenerative diseases, including dementia, Parkinson's, and ALS, across the United States. Founded by individuals with personal experiences in these conditions, the company offers a comprehensive suite of services that includes access to specialized neurologists, speech-language therapy, and 24/7 care coordination. Synapticure leverages advances in science and technology to ensure patients receive tailored treatment and support, fostering a holistic approach to care. By integrating various healthcare services, the platform simplifies access to essential medical resources, including behavioral health support, all designed to enhance the quality of life for those affected by neurodegenerative disorders.

64x Bio is a biotechnology company that specializes in accelerating the discovery of mammalian cell lines for biomanufacturing and therapeutic applications. The company has developed a high-throughput discovery and screening platform that integrates advanced computational design techniques. This platform enables the creation of highly optimized cell lines specifically tailored for the production of viral vectors, which are crucial for cell and gene therapies. By providing purpose-built genetically engineered cell lines, 64x Bio aims to enhance the efficiency of viral vector production, helping pharmaceutical and biotechnology companies improve their manufacturing capabilities while reducing associated costs.

PostEra is a company based in Santa Clara, California, founded in 2019, that specializes in medicinal chemistry services by integrating molecular design with chemical synthesis. It develops algorithms capable of predicting bioactivity even with limited data and outperforming human chemists in forecasting chemical reaction outcomes. PostEra collaborates with biopharma companies to advance small molecule programs while also developing its own internal pipeline. The company has led significant initiatives, including the COVID Moonshot, the world's largest open-science drug discovery effort.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatments through innovative therapies. The company specializes in the development of antibody-drug conjugates (ADCs), utilizing a unique protein engineering approach that enhances the effectiveness of these targeted therapies. Mythic Therapeutics' technology significantly improves the uptake of therapeutic agents in cancerous cells while minimizing their release in healthy cells, thereby increasing efficacy across various cancer types. This method not only boosts the potency of the treatments but also ensures a favorable safety profile, enabling healthcare providers to harness the full potential of ADCs. As such, Mythic Therapeutics aims to make a meaningful impact on cancer care by addressing a broad spectrum of tumor targets.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, that focuses on developing a cross-mammal drug discovery platform aimed at treating human diseases. Established in 2018 by a team of scientists with expertise in non-model organisms, the company investigates the biological mechanisms found in hibernating and deep-diving animals to uncover potential therapeutic applications for conditions such as heart disease and neurodegenerative disorders. By leveraging data from a diverse range of species, Fauna Bio aims to identify novel drug targets and facilitate pre-clinical and early clinical testing for new therapeutics, ultimately helping humans recover from serious medical emergencies like trauma, heart attacks, and strokes.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Bayesian Health Inc. is a digital health company headquartered in New York, New York, that specializes in developing an AI-driven platform designed to enhance patient care within hospital settings. The platform integrates with electronic medical records (EMR) systems to provide real-time data and actionable insights, allowing clinical staff and hospital leadership to monitor illness severity and detect changes in patient acuity. By leveraging artificial intelligence and machine learning, Bayesian Health's technology supports healthcare providers in making informed, data-driven decisions, thereby improving the efficiency and safety of patient care. Established in 2016, the company aims to optimize decision-making processes in complex clinical environments, ultimately increasing the capacity of frontline healthcare teams.

Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.

Sempre Health, Inc. is a healthcare technology company that operates a behavior-based healthcare pricing platform aimed at making prescription medications more affordable for patients. Founded in 2015 and based in San Francisco, the company collaborates with health plans and pharmaceutical manufacturers to dynamically adjust patients' co-payments based on their adherence to prescribed medications. By analyzing prescription records and individual patient behaviors, Sempre Health predicts the optimal price for medications at the point of sale. Patients receive personalized SMS notifications detailing potential discounts and guidance on improving their health, thereby encouraging timely prescription refills. This innovative approach not only enhances patient access to necessary medications but also contributes to better clinical outcomes while reducing overall healthcare costs. Additionally, Sempre Health is building a unique dataset on patient price sensitivities and cost behaviors to further refine its services.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, established in 2016. The company focuses on drug discovery and development for various protein misfolding diseases, which encompass neurological disorders such as Alzheimer's and Parkinson's diseases, as well as type-2 diabetes and several rare forms of amyloidosis. Wren Therapeutics leverages a proprietary technology platform that stems from extensive scientific research conducted at the University of Cambridge and Lund University. This platform enables Wren to develop small molecule therapeutics aimed at addressing the underlying mechanisms of these complex diseases.

Sitka Inc., established in 2018, operates a customizable video software platform that connects primary care providers with a network of virtual specialty providers. Based in San Francisco, California, Sitka's platform focuses on endocrinology, neurology, orthopedics, pulmonology, and rheumatology specialties, enabling efficient patient interactions and care delivery. The company aims to upskill primary care providers, collapse the care cycle, and enhance patient inclusion in specialty care within the U.S.

People Science is a technology-driven research and development platform focused on alternative medicine. The company facilitates connections between health-conscious individuals, medical professionals, and research scientists, fostering collaboration in the exploration of alternative therapeutic options. By assisting manufacturers in developing scientifically validated products, People Science aims to enhance consumer understanding of alternative medicines and their potential benefits for health and wellness. Through its innovative approach to clinical research, the company seeks to provide a comprehensive framework that supports the advancement of alternative medicine, ensuring that products are backed by rigorous scientific testing and research.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Woodstock, Georgia, focused on developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, dermatology, animal health, eye care, and oral care. With over 100 products commercialized in 33 countries, Sonoma addresses unmet medical needs through its innovative therapies aimed at chronic skin conditions. Key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for dermatoses; Celacyn gel for scar management; and SebuDerm for seborrheic dermatitis. Additionally, the company provides Microcyn, which targets various pathogens to promote wound healing, and Acuicyn, designed for eye care. Sonoma Pharmaceuticals was formerly known as Oculus Innovative Sciences, Inc. and has been incorporated since 1999. Its commitment to improving patient care and reducing healthcare costs is reflected in its diverse product portfolio that caters to both prescription and non-prescription needs.

TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, established in 2016. The company focuses on drug discovery and development for various protein misfolding diseases, which encompass neurological disorders such as Alzheimer's and Parkinson's diseases, as well as type-2 diabetes and several rare forms of amyloidosis. Wren Therapeutics leverages a proprietary technology platform that stems from extensive scientific research conducted at the University of Cambridge and Lund University. This platform enables Wren to develop small molecule therapeutics aimed at addressing the underlying mechanisms of these complex diseases.

Cricket Health Inc. is a specialty kidney care provider that focuses on delivering integrated nephrology and dialysis services for individuals with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Founded in 2015 and based in San Francisco, the company employs a technology-enabled, multidisciplinary approach to patient care, offering both in-person and virtual services. Cricket Health aims to enhance patient outcomes while providing value to healthcare partners by prioritizing patient health, reducing hospitalizations, facilitating access to transplants, and promoting home dialysis adoption. The company is dedicated to identifying at-risk patients early, managing disease progression, and delivering personalized care options such as transplant support and various dialysis modalities.

Sempre Health, Inc. is a healthcare technology company that operates a behavior-based healthcare pricing platform aimed at making prescription medications more affordable for patients. Founded in 2015 and based in San Francisco, the company collaborates with health plans and pharmaceutical manufacturers to dynamically adjust patients' co-payments based on their adherence to prescribed medications. By analyzing prescription records and individual patient behaviors, Sempre Health predicts the optimal price for medications at the point of sale. Patients receive personalized SMS notifications detailing potential discounts and guidance on improving their health, thereby encouraging timely prescription refills. This innovative approach not only enhances patient access to necessary medications but also contributes to better clinical outcomes while reducing overall healthcare costs. Additionally, Sempre Health is building a unique dataset on patient price sensitivities and cost behaviors to further refine its services.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Sitka Inc., established in 2018, operates a customizable video software platform that connects primary care providers with a network of virtual specialty providers. Based in San Francisco, California, Sitka's platform focuses on endocrinology, neurology, orthopedics, pulmonology, and rheumatology specialties, enabling efficient patient interactions and care delivery. The company aims to upskill primary care providers, collapse the care cycle, and enhance patient inclusion in specialty care within the U.S.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Floreo Inc., founded in 2016 and based in Washington D.C., develops a virtual reality learning app designed to teach social and communication skills to individuals with autism spectrum disorder, as well as those with ADHD and anxiety. The platform allows supervising adults to monitor and guide activities, making it a valuable tool for therapy clinics and school districts. Floreo is used by over 100 therapy clinic businesses and school districts, and has partnered with Meta to expand its reach in public schools.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company specializes in developing cell-permeable macrocyclic peptide therapeutics aimed at critical clinical targets. It employs proprietary computational design algorithms and innovative synthetic chemistry to create first-in-class macrocycle therapies that can be administered through various routes, including oral delivery. Circle Pharma's platform utilizes structure-based rational drug design and an iterative process to generate large virtual libraries of diverse macrocycle scaffolds, which are selected for their permeability. This approach enables the company to address challenging targets, particularly in the context of intracellular protein-protein interactions that play a significant role in cancer, thereby fulfilling unmet clinical needs. The company is led by David J. Earp.

Advantia Health, LLC is a healthcare delivery company based in Arlington, Virginia, founded in 2014. It specializes in providing comprehensive services in obstetrics and gynecology, primary care, and mental wellness, primarily focused on women's health and that of their families. The company operates additional locations in Virginia, Maryland, Illinois, and Missouri. Advantia Health utilizes technology to deliver high-quality, efficient care through outpatient facilities and offers telehealth services, enabling patients to connect with healthcare providers via web and mobile applications. This approach ensures that patients receive timely and appropriate medical guidance tailored to their needs.

Dr.Consulta is a Brazilian healthcare company that operates a network of clinics designed to provide quality medical care at affordable prices. Initially established as a full-service primary care provider, the company has since evolved into a Health Maintenance Organization (HMO) targeting uninsured individuals. Dr.Consulta offers a variety of outpatient services, including scheduled appointments, consultations, and examinations for general medical issues such as gynecology and pediatrics. By facilitating access to healthcare professionals, the company aims to deliver essential medical services to a wider population, ensuring that individuals can receive the care they need without financial strain.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Aspire Health, Inc. is a healthcare company based in Nashville, Tennessee, that specializes in outpatient palliative care for patients facing serious illnesses. Established in 2011, Aspire Health provides comprehensive medical care aimed at alleviating symptoms, pain, and stress associated with conditions such as cancer, congestive heart failure, chronic obstructive pulmonary disease, kidney failure, liver failure, advanced dementia, and amyotrophic lateral sclerosis. The company's services include navigating the healthcare system, guiding patients and caregivers through complex treatment decisions, and offering emotional and spiritual support. Aspire Health operates in multiple settings, including patients' homes, outpatient clinics, and assisted living centers, emphasizing disease management and care coordination. It serves a diverse clientele comprising patients, healthcare providers, and health plans across several counties in Middle Tennessee. As of June 2018, Aspire Health operates as a subsidiary of Nash Holding Company, LLC.

One Medical is a membership-based healthcare platform that offers a range of concierge medical services, combining digital health solutions with in-person care. Founded in 2007 and headquartered in San Francisco, California, the company aims to enhance the patient experience by providing seamless access to healthcare, including virtual video visits available at any time. By focusing on building personal relationships between healthcare providers and patients, One Medical seeks to improve health outcomes while reducing costs. The organization is committed to challenging the traditional healthcare model through its technology-powered, human-centered approach, ensuring that members receive high-quality care that is convenient and effective.

HeartFlow Inc., established in 2007 and headquartered in Redwood City, California, specializes in non-invasive coronary artery detection solutions. The company's flagship product, HeartFlow Analysis, employs artificial intelligence to generate a personalized 3D model of the heart using standard CT scan data. This enables clinicians worldwide to assess the impact of blockages on blood flow and determine optimal patient treatment, thereby reducing unnecessary invasive testing. HeartFlow operates additional offices in Portland (Oregon), Austin (Texas), London (UK), and Tokyo (Japan).

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.